September 17th, 2024 (Shanghai) — We are glad to announce that Dr. Chung-Hsin Wang, the General Manager of Trust Bio-sonics, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.
About Trust Bio-sonics
Trust Bio-sonics, based in Taiwan, is a global leader in microsphere technologies for contrast-enhanced ultrasound imaging and ultrasound-mediated drug delivery. The company focuses on cardiovascular diseases and cancer, striving to offer early diagnosis and treatment solutions for patients. Trust Bio-sonics’ leading diagnostic ultrasound imaging candidate, TBS-002 (a 505b1 New Drug), has commenced Phase 3 trials under the supervision of both the US FDA and Taiwan FDA. The company is also leveraging TBS-002’s technology in combination with portable ultrasound to create a platform, TBS-602, for drug delivery and efficacy enhancement in pancreatic cancer treatment and other medical applications, such as gene delivery. This platform has been shown to improve the effectiveness of conventional small-molecule chemotherapy drugs and large-molecule immunosuppressants, such as anti-PD-L1 immunotherapy. With its innovative approach and cutting-edge technology, Trust Bio-sonics is at the forefront of transforming patient care and advancing medical treatments worldwide.
About the speaker
Dr. Chung-Hsin Wang is the founder and inventor of Trust Bio-sonics’ technology. He graduated from the Department of Biomedical Engineering at National Tsing Hua University, where he pursued his Ph.D. focusing on the development of ultrasound microbubble contrast agents and therapeutic formulations for ultrasound-mediated drug delivery. During his doctoral studies, Dr. Wang published several key papers in the field, with over 800 citations to date.
Trust Bio-sonics’ leading product, TBS-002, is a next-generation ultrasound contrast agent new drug (505b1) that has entered Phase III clinical trials in both the U.S. and Taiwan. The goal is to provide a widely applicable ultrasound contrast agent and computer-aided diagnosis software, elevating ultrasound—our primary diagnostic tool—to achieve diagnostic excellence on par with enhanced CT and MRI imaging.
About ACCESS CHINA Partnering Forum
ACCESS CHINA Partnering Forum – Autumn Virtual Showcase is scheduled to be held on September 24th to 25th, and 27th, 2024, via Zoom webinar. This event helps biotechs/pharmas efficiently present their assets in front of 500+ healthcare companies and VCs online. During the event, audience can have access to innovative pharma and healthcare products from worldwide.
Conference Name: ACCESS CHINA Partnering Forum
Date & Time: Sep 24 – 25 (live), and 27 (VoD) 2024, China time
Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception
Scale: Expected 500+ participants Online; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs
View more information at https://biotochina.org/
REGISTER
To Register for ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact:
Wendi Xiang
BioToChina.org 